Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE). by Marchioni, A et al.
Lung Cancer
 
Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small
lung cancER with central Malignant airway Obstructions: a multicentric REtrospective
study (EVERMORE)
--Manuscript Draft--
 
Manuscript Number: LUNGCANCER-D-20-00885R1
Article Type: Research paper
Keywords: Non-small cell lung cancer;  central airway obstruction;  therapeutic bronchoscopy;
mechanical debulking;  airway stent;  KRAS-mutant tumors
Corresponding Author: Roberto Tonelli
ITALY
First Author: Alessandro Marchioni
Order of Authors: Alessandro Marchioni
Dario Andrisani
Roberto Tonelli
Roberto Piro
Alessandro Andreani
Gaia Cappiello
Emmanuela Meschiari
Massimo Dominici
Mario Bavieri
Fausto Barbieri
Sofia Taddei
Francesco Falco
Filippo Gozzi
Giulia Bruzzi
Riccardo Fantini
Luca Tabbì
Ivana Castaniere
Nicola Facciolongo
Enrico Clini
Abstract: Objectives
Despite new therapeutic perspectives, the presence of central airways occlusion
(CAO) in patients with locally advanced non-small cell lung cancer (NSCLC) is
associated with poor survival. There is no clear evidence on the clinical impact of
interventional bronchoscopy as a part of an integrated treatment to cure these patients.
Materials and methods
This retrospective cohort study was conducted in two teaching hospitals over a 10
years period (January 2010-January 2020) comparing patients with NSCLC at stage
IIIB and CAO at disease onset treated with chemotherapy/radiotherapy (standard
therapy-ST) with those receiving interventional bronchoscopy plus ST (integrated
treatment-IT). Primary outcome was 1-year survival. The onset of respiratory events,
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symptoms-free interval, hospitalization, need for palliation, and overall mortality served
as secondary outcomes.
Results
A total of 100 patients were included, 60 in the IT and 40 in the ST group. Unadjusted
Kaplan-Meier estimates showed greater effect of IT compared to ST on 1-year survival
(HR=2.1 95%CI[1.1-4.8], p=0.003). IT showed a significantly higher survival gain over
ST in those patients showing KRAS mutation (7.6 VS 0.8 months,<0.0001), a lumen
occlusion >65% (6.6 VS 2.9 months,<0.001), and lacking the involvement of left
bronchus (7 VS 2.3 months,<0.0001). Compared to ST, IT also showed a favorable
difference in terms of new hospitalizations (p=0.03), symptom-free interval (p=0.02),
and onset of atelectasis (p=0.01).
Conclusions
In patients with NSCLC stage IIIB and CAO, additional interventional bronchoscopy
might impact on 1-year survival. Genetic and anatomic phenotyping might allow
identifying those patients who may gain life expectancy from the endoscopic
intervention.
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Comments from Reviewer 1  
Reviewer 1 
Reviewer #1: Retrospective cohort study with control arm comparing n=60 interventional bronchoscopy at 
outset of treatment (predominantly stenting, some debulking) in addition to chemoradiotherapy vs 
chemoradiotherapy alone n=40 in malignant central airways obstruction in Stage IIIb NSCLC. Clinically and 
statistically significant primary outcome of improved 12 month survival. A nice study with a strong 
hypothesis forming outcome which may lead to more meaningful practice changing 
multicentre/prospective/randomised work. 
We really thank the Reviewer for the accurate reviewing process of our work. We are also grateful for the 
appreciation of our study. We have welcomed all of his/her comments and we have tried to amend the 
manuscript accordingly.  
 
Reviewer 1’s comment 1  
(1) Did all patients undergo initial flexible bronchoscopic workup?  
Response to Reviewer 1’s comment 1 
We thank the Reviewer for this observation that gave us the chance to better clarify each of the points 
risen.  
Response to Reviewers
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a) Figure 1 and 2nd line of Results/Population suggests this data was derived from CT scan. This can both 
over and underestimate the degree of luminal narrowing: in your reference number 6 for instance 31% 
of CAO was missed on dedicated CT scan review. Blood, mucous and endobronchial debris can 
overestimate obstructive effect of tumour. Was any note made of imaging/bronchoscopic correlation? 
And whether airway obstruction was intrinsic/extrinsic/mixed?  
We agree with the Reviewer that CT scan might under and/or overestimate the grade of CAO. All the 
patients enrolled had undergone flexible bronchoscopy whose reports were considered, alongside CT 
scan images, in order to estimate the extension of CAO. We have better specified this point in the 
methods section. Regarding the nature of the obstruction, we did not specify whether it was 
intrinsic/extrinsic/mixed given the paucity of data collected on this point due to the retrospective 
design of the study.  
b) How was diagnosis and staging of NSCLC performed? Given all stage IIIb (N2 or N3 disease), presume 
most via EBUS TBNA however a needle biopsy of a supraclavicular node may sufficiently make a 
diagnosis. 'Population and measures' does state 'histologic diagnosis' however -> these are cytologic 
methods unless cores are obtained. Were all diagnoses made histologically? 
We agree with the Reviewer that patients whose diagnosis was made via EBUS TBNA had a “cytologic” 
diagnosis and we have amended the manuscript accordingly. Given the long retrospective time frame 
(10 years) only a portion of patients was staged through EBUS TBNA. Thus, for all patients we have 
considered staging performed with PEC-CT scan assessment.  
c) Timeframe between diagnosis, interventional bronchoscopy procedures and chemoradiotherapy? 
We thank the Reviewer for this question. All patients enrolled were treated within a median time frame 
of 7 days (1-12) from diagnosis. Thereafter, they underwent sequential chemoradiotherapy within 5 (1-
8) days from the endoscopic treatment.  
d) Did any patients undergo debulking procedures via flexible bronchoscopy at time of diagnosis eg wire 
snare removal of polypoid endobronchial tumours? 
We thank the Reviewer for this question. None of the patients underwent debulking via flexible 
bronchoscopy but all of them were treated through rigid bronchoscopy.  
 
Reviewer 1’s comment 2 
(2) There is no mention of patient symptomatology in each group - I understand the retrospective nature 
doesn't lend itself to comparative symptom or quality of life scores but you do have symptom free time 
as a secondary outcome. 
Response to Reviewer 1’s comment 2 
We thank the Reviewer for this important comment. We have resumed available evidence of symptoms in 
a supplementary Table (see Table S2, supplementary materials).  
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Reviewer 1’s comment 3 
(3) Materials and Methods/Design states that a stent was used 'whenever indicated.' Can you please 
elaborate on this indication? Your reference 24 SPOC trial would suggest that stent placement post 
debulking of intrinsic tumour should not be considered in oncologic treatment naive patients (obviously 
recent paper, your data spans 10 years) 
Response to Reviewer 1’s comment 3 
We thank the Reviewer for this relevant comment that gave us the chance to better clarify the indication 
for stent positioning procedure at our center. Patients underwent stent positioning in case of mixed 
(intrinsic/extrinsic) CAO and if a significant (>50%) stenosis persisted after debulking. We have added this 
point in the Methods section of the revised version.  
a) Malignant CAO requiring stenting may use silicone or metal (covered or uncovered) stents. A brief 
comment on why silicone stents preferred? The implications of this choice, especially repeat 
procedures? Is the need for repeat bronchoscopy for stent management included in the secondary 
outcome 'hospitalisations?'   
We thank the Reviewer for this comment. The use of silicone stent was mainly motivated by center 
expertise in this material. Moreover, it allows a more extensive coverage of the lesion avoiding neoplastic 
infiltration within metal mesh. Furthermore, in our experience the ultimate nitinol covered metal stents are 
subjected to cover deterioration resulting in neoplastic infiltration. We included the need for repeated 
bronchoscopy in the outcome “hospitalisations”. 
b) Table 2 does address some of the above but - type of stent 'Y' and 'single' adds up to 58 (but stenting 
procedure n=54). Did some patients have dual stents placed? Are all complications at 1 year all stent 
complications and 10 individuals had differing permutations of these issues? The data in this table 
should be clearer. 
We thank the Reviewer for this comment. A number of patients had dual stent placement in case of 
extremely extensive CAO. The Table refers to the complications of patients who had integrated treatment 
(debulking only, stent only, debulking + stent). Ten patients presented the permutation of the different 
kind of complication over time (e.g. 6 patients presented occlusion and further dislocation and subsequent 
removal of the stent; of them 5 patients presented post-obstructive pneumonia, 2 patient presented 
granulation and one of them underwent stent removal, 2 patients presented dislocation without occlusion 
and were further subjected to removal). We have added this clarification in the legend of Table 2.  
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Reviewer 1’s comment 4 
(4) Did any patients in the standard care group require interventional bronchoscopy techniques during 
their treatment course? Would expect some given the significant degree of obstruction at time of 
diagnosis, the high rates of respiratory failure and palliative treatments depicted in table 4. 
 Response to Reviewer 1’s comment 4 
We thank the Reviewer for this comment. None of the patient in the standard care group underwent 
interventional bronchoscopy during the treatment course.  
 
Reviewer 1’s comment 5 
(5) KRAS mutation status and left main bronchus involvement are known poor prognostic features. These 
are first flagged in the statistical analysis and appropriate background provided in the discussion 
section. Should these at least be touched upon in the introduction? 
Response to Reviewer 1’s minor comment 5 
We welcome and thank the Reviewer for this comment. We have added a brief sentence in the 
introduction section to tackle with this concept as follows: “….although some anatomical features (i.e. left 
bronchus involvement) alongside specific mutational status may worsen outcomes”. 
 
Reviewer 1’s comment 6 
(6) In your discussion you want to consider the real advantage in survival. I would be interested in 
subgroups of debulking/stenting/both, hypothesising that the act of debulking intrinsic disease 
(perhaps more so in the KRAS mutant patients) has a greater impact and augmentation of subsequent 
therapy than stenting alone. The numbers would likely be small however and is hypothesis forming at 
best. The intervention being investigated is one or both of two procedures, in patients who may have 
intrinsic/extrinsic or mixed central airway obstruction. There remains inherent inescapable 
heterogeneity. Non-surgically appropriate IIIa patients with CAO could well have been included (but 
more challenging data retrieval) and may provide a more meaningful future recommendation. It should 
be mentioned why only IIIb were included. Agree with comment regarding studies including stage IV 
disease having an additional confounder.   
Response to Reviewer 1’s minor comment 6 
We thank the Reviewer for these important comments. We have then run a new analysis by treatment 
subgroups. Although the limited group numbers, we found that debulking alone was associated with higher 
incidence of respiratory failure and re-hospitalization. The associated treatment between debulking and 
stenting resulted as the more effective treatment although small numbers did not allow to get any 
statistical significance. We have added Table S3 in the supplementary materials and a specific section in the 
Results. This point deserves to be further investigated in larger cohorts.  
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Regarding the potential inclusion of patient with stage 3A we agree with the Reviewer that those patients 
could have benefit from interventional treatment. However, we decided to include only stage 3B in order 
to obtain a more reliable survival gain in the analysis. We have thus added this point in the discussion 
section.  
 
Reviewer 1’s comment 7 
(7) Table 1 lists PDL-1 n(%). Is this tumour proportion score? This is a continuous rather than binary 
variable. What percentage cutoff for PDL-1 is being used here? 
Response to Reviewer 1’s comment 7 
We thank the Reviewer for this comment. PDL-1 feature is referred to patients with a PDL-1 expression 
above 50%. This point has been better specified in the revised version. 
 
Reviewer 1’s comment 8 
(8) How has 'extensive involvement' been defined? Table 1 would suggest the numbers are the same as 
carina involvement? 
Response to Reviewer 1’s comment 8 
We thank the Reviewer for this comment. Extensive involvement was defined as the involvement of 
trachea, carina and at least one main bronchus. The Reviewer correctly pointed out that the number of 
patients with the involvement of carina is the same of patients with extensive involvement. This might 
mean that in our population there were no patients with carina involvement without a simultaneous 
involvement of trachea and main bronchi. 
 
Reviewer 1’s comment 9 
(9) Table 1 Histotype 'others' - what does this include? Predominantly NOS? 
Response to Reviewer 1’s comment 9 
We thank the Reviewer for this comment. The feature “Histotype others” includes predominantly NOS 
(n=10, 67%) alongside large cells carcinoma (n=5, 33%). This point has been better specified in the revised 
version. 
 
Reviewer 1’s comment 10 
(10) I feel highlights should be written in past tense - this study showed that x IMPROVED y, that doesn't 
mean that x IMPROVES y. Try to avoid acronyms in highlights. 
Response to Reviewer 1’s comment 10 
We thank the Reviewer for this comment. We have amended highlights as suggested.  
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Highlights 
x In a cohort of patients with locally advanced Non-Small Cell Lung Cancer and associated Central 
Airways Obstruction interventional bronchoscopy as a part of an integrated treatment improved 
1-year survival.  
x Interventional bronchoscopy reduced new hospitalizations, increased symptom-free interval 
and prevented atelectasis.  
x Genetic and anatomic phenotyping might identify patients who may gain life expectancy from 
the endoscopic intervention. 
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Abstract 
Objectives 
Despite new therapeutic perspectives, the presence of central airways occlusion (CAO) in patients 
with locally advanced non-small cell lung cancer (NSCLC) is associated with poor survival. There is 
no clear evidence on the clinical impact of interventional bronchoscopy as a part of an integrated 
treatment to cure these patients.  
Materials and methods 
This retrospective cohort study was conducted in two teaching hospitals over a 10 years period 
(January 2010-January 2020) comparing patients with NSCLC at stage IIIB and CAO at disease onset 
treated with chemotherapy/radiotherapy (standard therapy-ST) with those receiving interventional 
bronchoscopy plus ST (integrated treatment-IT). Primary outcome was 1-year survival. The onset of 
respiratory events, symptoms-free interval, hospitalization, need for palliation, and overall mortality 
served as secondary outcomes.  
Results 
A total of 100 patients were included, 60 in the IT and 40 in the ST group. Unadjusted Kaplan-Meier 
estimates showed greater effect of IT compared to ST on 1-year survival (HR=2.1 95%CI[1.1-4.8], 
p=0.003). IT showed a significantly higher survival gain over ST in those patients showing KRAS 
mutation (7.6 VS 0.8 months,<0.0001), a lumen occlusion >65% (6.6 VS 2.9 months,<0.001), and 
lacking the involvement of left bronchus (7 VS 2.3 months,<0.0001). Compared to ST, IT also showed 
a favorable difference in terms of new hospitalizations (p=0.03), symptom-free interval (p=0.02), 
and onset of atelectasis (p=0.01). 
Conclusions 
In patients with NSCLC stage IIIB and CAO, additional interventional bronchoscopy might impact on 
1-year survival. Genetic and anatomic phenotyping might allow identifying those patients who may 
gain life expectancy from the endoscopic intervention. 
 
 
Key words: Non-small cell lung cancer, central airway obstruction, therapeutic bronchoscopy, 
mechanical debulking, airway stent, KRAS-mutant tumors. 
Abbreviations: CAO = central airway obstruction, CT = chemotherapy, RT = radiation therapy, ST = 
standard therapy, IT integrated treatment, NSCLC = Non-Small Cell Lung Cancer, IQR = interquartile 
ranges; EGFR = epidermal growth factor receptor; BRAF = v-raf murine sarcoma viral oncogene 
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homolog B1; KRAS = Kirsten rat sarcoma; ALK = Anaplastic lymphoma kinase; PDL1 = programmed 
death-ligand 1; CHT = chemotherapy; RT = radiotherapy; TKI = tyrosine kinase inhibitor. 
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Introduction 
Stage III locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous condition affecting 
about one-third of the overall patients (1). Usually, therapeutic approach consists of a combination 
of local therapy (radiotherapy) with systemic platinum-based doublet chemotherapy. However, the 
prognosis remains poor, with only a limited improvement in survival achieved over the past 10 
years. Recently, it has been shown that durvalumab significantly prolonged progression-free and 
overall survival, as compared with placebo, among patients with unresectable stage III NSCLC after 
concurrent chemoradiotherapy (2-3). Despite this new therapeutic perspective, a group of patients 
with locally advanced NSCLC already presents at diagnosis with an occlusion of the central airways 
which can result in worse life expectancy.  
Malignant central airway obstruction (CAO) is defined as any malignant disease process that causes 
significant alteration of patency of the trachea, main bronchi, or bronchus intermedius (4). It is 
estimated that 20-30% of patients with lung cancer will develop CAO with the associated 
complications (dyspnoea, atelectasis, post-obstructive pneumonia), and 40% of tumor-related 
mortality can be attributed to locoregional progression of lung cancer (5). Furthermore, some 
studies show that in advanced lung cancer, CAO is associated with poor survival when adjusted for 
age, gender and stage of cancer (6). In particular, in unresectable NSCLC stage IIIB with CAO, 
locoregional control of neoplastic disease could have a significant impact on survival.  
Short-course of palliative radiotherapy may achieve significant control of airway stenosis in 23-54% 
of patients within 24 days (7-8). Interventional bronchoscopy (mechanical debulking and thermal 
techniques or implementation with tracheal/bronchial prostheses) allows for immediate relieving 
of airway occlusion in 93% of cases, leading to a significant improvement in symptoms and quality 
of life in almost 50% of patients (9).  
To date, there is currently no reliable evidence regarding the impact of interventional bronchoscopy 
on survival in locally advanced NSCLC (10). The main purpose of this study is therefore to evaluate 
the clinical impact of interventional bronchoscopy plus chemotherapy/radiotherapy (integrated 
treatment) compared with chemotherapy/radiotherapy alone (standard therapy) in the 
management of patients with stage IIIB NSCLC with CAO. 
 
Materials and methods 
Design 
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EVERMORE is a retrospective, multicenter observational cohort study carried out in two units of 
Emilia Romagna region (Italy): Diagnostic and Interventional Bronchoscopy Unit of the University 
Hospital of Modena, and Thoracic Endoscopy Unit of the Santa Maria Nuova Hospital of Reggio 
Emilia. The two units have different protocols routinely applied to treat CAO in locally advanced 
NSCLC. In center A endoscopic treatment is performed early when stenosis exceeds 50%, even in 
the absence of respiratory symptoms, while in center B the other endoscopic treatment is 
performed only in CAO with associated respiratory symptoms. All interventional procedures have 
been performed in the operating room with a Dumon rigid bronchoscope (Efer Medical, La Ciotat, 
Cedex, France) under general anesthesia. Neodymium-doped yttrium aluminium garnet (Nd-YAG) 
laser photoresection (KLS Martin, Diode-pumped Nd: YAG laser Limax ®, Germany) was performed 
at 15-30 watts and pulse duration of 0.5-1.0s. In cases with extrinsic compression from malignant 
occlusion, or whenever indicated, a silicone stent (NOVATECH Doumon stents, Boston Medical 
Products, Inc., Westborough, MA, USA) was placed. 
Malignant CAO was defined as a luminal occlusion of > 50% in the trachea, mainstem bronchi and/or 
bronchus intermedius, consistent with previous studies (9). Clinical staging was based on the 8th 
lung cancer TNM classification (11). 
This study was approved by Local Ethics Committee (Prot. AOU 0013040/19 and 
276/2019/OSS/AOUMO) and registered on clinicaltrial.gov (trial registration number: 
NCT03903315).  
 
Population and measures 
From January 2010 to January 2020 we collected clinical, endoscopic and radiological data of NSCLC 
patients with CAO admitted in the two units. Inclusion criteria were as follows: age >18 years, 
candidates for anticancer treatment with histologic diagnosis of NSCLC stage IIIB and CAO at onset 
of disease, performance status < 2, CAO in between 50% and 80%. Patients were excluded if aged > 
80, and/or with end-stage chronic obstructive pulmonary disease, interstitial lung disease, life-
threatening stenosis requiring urgent endoscopy. 
Chart review, health record, medical record, archival data analysis was performed at each center. 
The following data have been collected in an electronic database: demographic data, Charlson Index 
for comorbidity assessment, histopathology, genetic analysis of the tumor (EGFR and KRAS 
mutations, ALK translocations), PD-L1 expression, localization of CAO, degree of airway obstruction, 
the type of anticancer treatment (chemotherapy, radiotherapy, tyrosine kinase inhibitors, 
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immunotherapy), type of endoscopic treatment (stent, laser and mechanical debulking), 
complications of endoscopic treatment, onset of respiratory events (atelectasis, infections, 
respiratory failure, hemorrhage), 1-year and overall survival, hospitalization rate, need for palliative 
care, symptoms-free interval. Patients included were divided into two groups: 1) integrated 
treatment-IT (patients undergoing endoscopic treatment plus chemotherapy/radiotherapy); 2) 
standard treatment-ST (chemotherapy/radiotherapy alone). 
 
Outcomes 
The primary purpose was to evaluate the impact on 12-month survival in patients with stage IIIB 
NSCLC with CAO in the two groups.  
The secondary aim was similarly to compare the onset of respiratory events, hospitalization, need 
for palliative care, symptoms-free interval and overall survival (see in the previous paragraph). 
 
Statistical Analysis 
Sample size calculation was performed assuming an estimated 1-year mortality rate of 45% for IIIB 
NSCLC patients receiving ST with an estimated reduction by 40% in those receiving IT (data derived 
from an exploration analysis in 15 patients). Assuming α= 0.05, power 80% and an enrollment ratio 
of 1:1.5 (according to the overall number of patients referred at each center), a sample size of 100 
patients was calculated to perform analysis on the primary outcome.  
Baseline characteristics of the participants treated with IT and ST were compared. Continuous 
variables were expressed as median and interquartile ranges (IQR) and compared by Kruskal Wallis 
test. Categorical variables were expressed as numbers and percentages (%) and compared by χ2 test 
or Fisher’s exact test across the integrated and the standard treatment groups.  
The 1-year survival analysis was performed with participants’ follow-up accrued from the date of 
diagnosis until death. Time to death by groups was compared using unweighted Kaplan-Meier 
curves and univariable and multivariable Cox regression analysis with baseline fixed covariates. The 
effect of treatment was shown by means of unadjusted and adjusted hazard ratio (HR) with 95%CI. 
Two key confounders were identified as carina involvement and extensive involvement, as the most 
likely causes of treatment group assignment and outcome risk.  In order to test the hypothesis that 
the difference between treatment groups might vary according to mutational status, severity of 
CAO and unfavorable location of the stenosis, we formally included an interaction term in the Cox 
regression model. Results were then showed after categorizing the population in two strata using 
 10 
alternatively categorical separation for dichotomous variables (KRAS mutational status and left 
bronchus involvement) and the overall median value for continuous variables (percentage of lumen 
occlusion). Overall survival gain has been assessed according to the abovementioned stratification 
through ANOVA. The impact of the two different treatments on pre-specified secondary outcomes 
was carried out through Fisher’s exact test. A two-sided test of less than 0.05 was considered 
statistically significant.  
Statistical analyses were performed using SPSS version 25.0 (IBM Corp.New York, NY, USA) and 
Graphpad prism version 8.0 (Graphpad Software, Inc. La Jolla, Ca, USA) unless otherwise indicated. 
 
 
Results 
Population 
A total amount of 7243 patients diagnosed with NSCLC were referred to center A and B over the 
considered period. Out of them, 730 (10%) presented CAO > 50% at the CT scan at the time of 
diagnosis. Among the 188 eligible subjects, 100 patients with CAO and stage IIIB NSCLC were 
included in the study. Their median follow-up from diagnosis was 21 (IQR=9-36) months. Study flow-
chart is shown in Figure 1.  
Demographics, type and site of malignancies, degree of CAO, mutational state of cancer and 
oncological therapies are presented in Table 1. Forty patients who underwent cancer therapy alone, 
represented the ST group, whereas 60 patients of the IT group underwent endoscopic treatment 
plus standard chemotherapy/radiotherapy. The two groups did not show differences in terms of 
demographic characteristics, degree of stenosis, histology, mutational status of cancer and modality 
of standard treatment (Table 1). Patients in IT group showed an higher prevalence of extensive 
stenosis (25% VS 5%, p=0.01) and carina involvement (25% VS 5%, p=0.01) as compared to ST.  
Overall, 90 patients received sequential chemo-radiotherapy with no difference between groups 
(p=0.5). Groups did not differ in the type of chemotherapy received (Table S1, supplementary 
materials). Types of recanalization techniques and complications related to endoscopic intervention 
as reported in the IT group are shown in Table 2.  
 
Outcomes 
Unadjusted Kaplan-Meier estimates showed the beneficial effect of IT compared to ST on 1-year 
survival (HR=2.1 95%CI[1.1-4.8], p=0.003) (Figure 2, panel A). After controlling for the key identified 
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confounders of carina and extensive involvement results were almost superimposable confirming 
the treatment difference observed in the unadjusted analysis (Table 3). Moreover, the stratified 
analyses showed that this difference varied by the degree of occlusion, the lack of main bronchus 
involvement, and the KRAS molecular status (Table 3) even after adjusting for the usual set of 
confounders. Kaplan-Meier curves also showed a significant survival benefit at 1-year for the 
abovementioned patients’ strata when receiving IT as compared with ST (Figure A, panel B-D). 
Overall survival was longer in IT group although not statistically significant (23.7 months VS 19.2 
months, p=0.2). IT group showed a significantly higher survival gain over ST when patients had KRAS 
mutation (7.6 months VS 0.8 months, <0.0001), a lumen occlusion > 65% (6.6 months VS 2.9 months, 
<0.001), and no involvement of left bronchus (7 months VS 2.3 months, <0.0001) (Figure 3).  
Finally, IT showed a statistically significant favorable difference in terms of overall new 
hospitalizations (p=0.03), symptom-free interval (p=0.02), and onset of atelectasis (p=0.01), but not 
for occurrence of infections or hemorrhage (p=0.7 and p=0.8 respectively), onset of respiratory 
failure (p=0.1),  use of palliative care (p=0.9) (Table 4).  
 
Discussion 
This study shows that the integration of interventional bronchoscopy (used outside palliation) with 
chemotherapy/radiotherapy in the management of IIIB NSCLC with CAO has a significant impact on 
the patient's prognosis. Moreover, the greater gain in life expectancy would be closely related to 
cancer’s anatomical (airway occlusion> 65%, no left mainstem occlusion), and molecular (KRAS-
mutant NSCLC) features.  
The prognosis of stage IIIB lung cancer is poor, and local control as well as systemic treatment are 
essential. The standard of care in unresectable stage III disease is a combination of platinum-based 
chemotherapy with radiation therapy (1). In recent years, the introduction of target therapy and 
immune-checkpoint inhibitors opened up new perspectives of treatment. In particular, the synergic 
effect between immune therapy and radiotherapy has been recently proved, thus this combination 
has become a new standard in stage III patients (2,3,12).  
A proportion of IIIB NSCLC has a central airway occlusion that can occur at onset or during the course 
of the disease (4-5). In these patients, loco-regional progression of the disease can be one of the 
main causes of cancer-related death. Therefore, timing and technique of local disease control could 
have a significant impact on survival. Interventional bronchoscopy allows for rapid recanalization of 
airway obstruction, and it can be useful in locoregional control, by integrating with chemo-radiant 
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treatment in patients with locally advanced NSCLC (10). Some studies show that the technical 
success rate of this treatment, defined as restoration of airway patency of at least 50% of the original 
airway diameter, approximates 90% in experienced centers (9, 13-14).  
Although the role of interventional bronchoscopy in the palliation of symptoms is well recognized, 
no data are currently available on the prognostic impact when using this technique in association 
with chemo/radiotherapy in stage IIIB NSCLC. Retrospectively, we were able to show a clear 1-year 
survival advantage when local interventional bronchoscopy is combined with medical therapies in 
patients with CAO.  
Although this result appears relevant, some considerations must be taken regarding the timing of 
intervention, the real impact of the technique on life expectancy, and the influence of cancer’s 
molecular features. 
First, the threshold of airway narrowing requiring interventional bronchoscopy is not standardized. 
Being considered palliative, endoscopic intervention is often performed when symptoms are 
present, and the degree of obstruction is very severe (10). Dyspnea in patients with CAO is not 
related to the alteration of gas exchange, but to the increased work of breathing required to 
maintain a normal flow of air delivered to and from the lung. Therefore, at least theoretically, 
pressure drop (ΔP) over the stenosis is the main parameter that can be considered as a cause of 
increased work of breathing and appearances of symptoms. In a computational fluid dynamics (CFD) 
study, flow patterns and ΔP over different degrees of tracheal stenosis artificially inserted into a 
three-dimensional upper airway model were assessed. ΔP over the stenosis was seen to increase 
dramatically only if >70% of tracheal lumen was occluded (15). Thus, bronchoscopy treatment in 
NSCLC is often proposed when the narrowing of the airways is extreme, and the risks of the 
intervention can be relevant. In our cohort, we therefore excluded patients with severe stenosis 
(>80%) and patients who required emergency intervention due to respiratory distress. 
Notwithstanding, present data suggest that interventional bronchoscopy over standard treatment, 
may have a potential impact on outcome when proposed early in the management of stage IIIB 
NSCLC with CAO.  
Second, we should consider which is the real advantage in survival following interventional 
bronchoscopy in stage IIIB NSCLC. Previous studies have analyzed the outcome of NSCLC patients 
undergoing interventional bronchoscopy in an heterogeneous populations, mixing up locally 
advanced NSCLC and stage IV, without a reliable control group, providing inconclusive results (16-
24). Some data suggest that there is no difference in survival between patients free from CAO 
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receiving chemotherapy, compared to those symptomatics who underwent successful 
interventional bronchoscopy followed by adjuvant chemotherapy (16). In our study, the different 
approach to endoscopic treatment of CAO (stenosis > 50%) allowed the enrollment of a reliable 
control group. In addition, only stage IIIB patients were considered for the study main purpose. 
Indeed, 1-year survival significantly improved in the IT group compared to ST, however, if we 
consider the gain in life expectancy, a substantial survival effect was found in specific subsets of 
patients. Obstruction > 65% of the airway lumen, and no left mainstem occlusion were two 
anatomical features associated with a significant gain in survival. While it may be intuitive that 
resolving airway obstruction > 65% can result in a survival advantage, the explanation regarding the 
involvement of the left mainstem on the prognosis is less self-evident. Several studies have 
evaluated the technical success rate of therapeutic bronchoscopy in CAO, raising up the issue of 
patient selection (9,25). In the multi-institutional ACCP Quality Improvement Registry Evaluation, 
and Education (AQuIRE) registry, left mainstem obstruction was an unfavorable factor for the 
technical success of interventional bronchoscopy (9). Therefore, this result in our study could be 
explained by the greater technical difficulty in performing rigid bronchoscopy in cases of CAO with 
distal involvement of the left main bronchus.  
Third, molecular cancer features also had the greatest impact on gain in life expectancy. In our 
cohort, patients with KRAS-mutant NSCLC had 7.6 months gain in life expectancy in IT patients 
compared to ST. Although there is no a valid cut-off to define the survival gain as clinically relevant, 
some studies indicate a threshold greater than 4-5 months to consider a solid therapeutic progress 
(26-28). Moreover, considering that unresectable stage IIIB NSCLC is an aggressive disease with poor 
outcome, the gain in life expectancy found in the IT group is an impressive result. KRAS mutations 
are found in approximately 20-25% of lung adenocarcinomas in Western countries and in 10-15% 
of cases in Asia (29-31). The mutation occurs mainly at codon 12 (>80%) and 13, causing a 
constitutive activation of the RAS oncoprotein and its intracellular pathways, resulting in 
uncontrolled cell proliferation and abnormal cell survival (32). Considering that KRAS-mutant lung 
cancer has been generally associated with lower survival and lower sensitivity to chemotherapy or 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, it is reasonable to assume that 
in this subset of patients standard chemotherapy/radiotherapy is unable to achieve the local control 
of occlusive disease. 
Although present findings are intriguing, we cannot draw a definitive conclusion due to several 
limitations of the study. This is mainly because of the retrospective design and the limited sample 
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size, whose calculation might have been biased. Last, patients have been treated in centers with 
high expertise in interventional pulmonology, therefore the validity of data cannot be extrapolated 
for all. Notwithstanding, results are promising and suggest that, interventional bronchoscopy should 
be considered early as an integral part of management of patients with NSCLC stage IIIB and CAO. 
 
Conclusions 
In patients with NSCLC stage IIIB and associated CAO, interventional bronchoscopy does not target 
only a palliative purpose but might impact survival. Genetic and anatomic phenotyping might allow 
identifying those patients who are more likely to gain in life expectancy from endoscopic 
intervention. Further prospective investigations in larger cohorts is warranted to confirm results.  
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Figure legends 
Fig. 1. Flow chart for patients in this study. 
 
Fig. 2. Kaplan-Mayer curves showing impact of integrated treatment compared to standard therapy 
on 1-year survival for the overall population (panel A), for patients presenting K-RAS mutation (panel 
B), for patients with lumen occlusion > 65% (panel C) and for patients with lack of left bronchus 
involvement (panel D).   
 
Fig. 3. Comparison of survival gain of integrated treatment over standard therapy for patients 
presenting K-RAS mutation (left side), for patients with lumen occlusion > 65% (central part) and for 
patients with lack of left bronchus involvement (right side).   
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Abstract 
Objectives 
Despite new therapeutic perspectives, the presence of central airways occlusion (CAO) in patients 
with locally advanced non-small cell lung cancer (NSCLC) is associated with poor survival. There is 
no clear evidence on the clinical impact of interventional bronchoscopy as a part of an integrated 
treatment to cure these patients.  
Materials and methods 
This retrospective cohort study was conducted in two teaching hospitals over a 10 years period 
(January 2010-January 2020) comparing patients with NSCLC at stage IIIB and CAO at disease onset 
treated with chemotherapy/radiotherapy (standard therapy-ST) with those receiving interventional 
bronchoscopy plus ST (integrated treatment-IT). Primary outcome was 1-year survival. The onset of 
respiratory events, symptoms-free interval, hospitalization, need for palliation, and overall mortality 
served as secondary outcomes.  
Results 
A total of 100 patients were included, 60 in the IT and 40 in the ST group. Unadjusted Kaplan-Meier 
estimates showed greater effect of IT compared to ST on 1-year survival (HR=2.1 95%CI[1.1-4.8], 
p=0.003). IT showed a significantly higher survival gain over ST in those patients showing KRAS 
mutation (7.6 VS 0.8 months,<0.0001), a lumen occlusion >65% (6.6 VS 2.9 months,<0.001), and 
lacking the involvement of left bronchus (7 VS 2.3 months,<0.0001). Compared to ST, IT also showed 
a favorable difference in terms of new hospitalizations (p=0.03), symptom-free interval (p=0.02), 
and onset of atelectasis (p=0.01). 
Conclusions 
In patients with NSCLC stage IIIB and CAO, additional interventional bronchoscopy might impact on 
1-year survival. Genetic and anatomic phenotyping might allow identifying those patients who may 
gain life expectancy from the endoscopic intervention. 
 
 
Key words: Non-small cell lung cancer, central airway obstruction, therapeutic bronchoscopy, 
mechanical debulking, airway stent, KRAS-mutant tumors. 
Abbreviations: CAO = central airway obstruction, CT = chemotherapy, RT = radiation therapy, ST = 
standard therapy, IT integrated treatment, NSCLC = Non-Small Cell Lung Cancer, IQR = interquartile 
ranges; EGFR = epidermal growth factor receptor; BRAF = v-raf murine sarcoma viral oncogene 
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homolog B1; KRAS = Kirsten rat sarcoma; ALK = Anaplastic lymphoma kinase; PDL1 = programmed 
death-ligand 1; CHT = chemotherapy; RT = radiotherapy; TKI = tyrosine kinase inhibitor. 
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Introduction 
Stage III locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous condition affecting 
about one-third of the overall patients (1). Usually, therapeutic approach consists of a combination 
of local therapy (radiotherapy) with systemic platinum-based doublet chemotherapy. However, the 
prognosis remains poor, with only a limited improvement in survival achieved over the past 10 
years. Recently, it has been shown that durvalumab significantly prolonged progression-free and 
overall survival, as compared with placebo, among patients with unresectable stage III NSCLC after 
concurrent chemoradiotherapy (2-3). Despite this new therapeutic perspective, a group of patients 
with locally advanced NSCLC already presents at diagnosis with an occlusion of the central airways 
which can result in worse life expectancy.  
Malignant central airway obstruction (CAO) is defined as any malignant disease process that causes 
significant alteration of patency of the trachea, main bronchi, or bronchus intermedius (4). It is 
estimated that 20-30% of patients with lung cancer will develop CAO with the associated 
complications (dyspnoea, atelectasis, post-obstructive pneumonia), and 40% of tumor-related 
mortality can be attributed to locoregional progression of lung cancer (5). Furthermore, some 
studies show that in advanced lung cancer, CAO is associated with poor survival when adjusted for 
age, gender and stage of cancer (6). In particular, in unresectable NSCLC stage IIIB with CAO, 
locoregional control of neoplastic disease could have a significant impact on survival.  
Short-course of palliative radiotherapy may achieve significant control of airway stenosis in 23-54% 
of patients within 24 days (7-8). Interventional bronchoscopy (mechanical debulking and thermal 
techniques or implementation with tracheal/bronchial prostheses) allows for immediate relieving 
of airway occlusion in 93% of cases, leading to a significant improvement in symptoms and quality 
of life in almost 50% of patients, although some anatomical features (i.e. left bronchus involvement) 
alongside specific mutational status may worsen outcomes. (9) 
To date, there is currently no reliable evidence regarding the impact of interventional bronchoscopy 
on survival in locally advanced NSCLC (10). The main purpose of this study is therefore to evaluate 
the clinical impact of interventional bronchoscopy plus chemotherapy/radiotherapy (integrated 
treatment) compared with chemotherapy/radiotherapy alone (standard therapy) in the 
management of patients with stage IIIB NSCLC with CAO. 
 
Materials and methods 
Design 
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EVERMORE is a retrospective, multicenter observational cohort study carried out in two units of 
Emilia Romagna region (Italy): Diagnostic and Interventional Bronchoscopy Unit of the University 
Hospital of Modena, and Thoracic Endoscopy Unit of the Santa Maria Nuova Hospital of Reggio 
Emilia. The two units have different protocols routinely applied to treat CAO in locally advanced 
NSCLC. In center A endoscopic treatment is performed early when stenosis exceeds 50%, even in 
the absence of respiratory symptoms, while in center B the other endoscopic treatment is 
performed only in CAO with associated respiratory symptoms. In center A patients underwent stent 
positioning in case of mixed (intrinsic/extrinsic) CAO and if after debulking procedure a significant 
(>50%) stenosis persists. All interventional procedures have been performed in the operating room 
with a Dumon rigid bronchoscope (Efer Medical, La Ciotat, Cedex, France) under general anesthesia. 
Neodymium-doped yttrium aluminium garnet (Nd-YAG) laser photoresection (KLS Martin, Diode-
pumped Nd: YAG laser Limax ®, Germany) was performed at 15-30 watts and pulse duration of 0.5-
1.0s. In cases with extrinsic compression from malignant occlusion, or whenever indicated, a silicone 
stent (NOVATECH Doumon stents, Boston Medical Products, Inc., Westborough, MA, USA) was 
placed. 
All patients had undergone flexible bronchoscopy whose reports were considered, alongside CT 
scan images, in order to estimate the extension of CAO. Malignant CAO was defined as a luminal 
occlusion of > 50% in the trachea, mainstem bronchi and/or bronchus intermedius, consistent with 
previous studies (9). Clinical staging was based on the 8th lung cancer TNM classification (11). 
This study was approved by Local Ethics Committee (Prot. AOU 0013040/19 and 
276/2019/OSS/AOUMO) and registered on clinicaltrial.gov (trial registration number: 
NCT03903315).  
 
Population and measures 
From January 2010 to January 2020 we collected clinical, endoscopic and radiological data of NSCLC 
patients with CAO admitted in the two units. Inclusion criteria were as follows: age >18 years, 
candidates for anticancer treatment with cytologic and/or histologic diagnosis of NSCLC stage IIIB 
and CAO at onset of disease, performance status < 2, CAO in between 50% and 80%. Patients were 
excluded if aged > 80, and/or with end-stage chronic obstructive pulmonary disease, interstitial lung 
disease, life-threatening stenosis requiring urgent endoscopy. 
Chart review, health record, medical record, archival data analysis was performed at each center. 
The following data have been collected in an electronic database: demographic data, Charlson Index 
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for comorbidity assessment, histopathology, genetic analysis of the tumor (EGFR and KRAS 
mutations, ALK translocations), PD-L1 expression, localization of CAO, degree of airway obstruction, 
the type of anticancer treatment (chemotherapy, radiotherapy, tyrosine kinase inhibitors, 
immunotherapy), type of endoscopic treatment (stent, laser and mechanical debulking), 
complications of endoscopic treatment, onset of respiratory events (atelectasis, infections, 
respiratory failure, hemorrhage), 1-year and overall survival, hospitalization rate, need for palliative 
care, symptoms-free interval. Patients included were divided into two groups: 1) integrated 
treatment-IT (patients undergoing endoscopic treatment plus chemotherapy/radiotherapy); 2) 
standard treatment-ST (chemotherapy/radiotherapy alone). 
 
Outcomes 
The primary purpose was to evaluate the impact on 12-month survival in patients with stage IIIB 
NSCLC with CAO in the two groups.  
The secondary aim was similarly to compare the onset of respiratory events, hospitalization, need 
for palliative care, symptoms-free interval and overall survival (see in the previous paragraph). 
 
Statistical Analysis 
Sample size calculation was performed assuming an estimated 1-year mortality rate of 45% for IIIB 
NSCLC patients receiving ST with an estimated reduction by 40% in those receiving IT (data derived 
from an exploration analysis in 15 patients). Assuming α= 0.05, power 80% and an enrollment ratio 
of 1:1.5 (according to the overall number of patients referred at each center), a sample size of 100 
patients was calculated to perform analysis on the primary outcome.  
Baseline characteristics of the participants treated with IT and ST were compared. Continuous 
variables were expressed as median and interquartile ranges (IQR) and compared by Kruskal Wallis 
test. Categorical variables were expressed as numbers and percentages (%) and compared by χ2 test 
or Fisher’s exact test across the integrated and the standard treatment groups.  
The 1-year survival analysis was performed with participants’ follow-up accrued from the date of 
diagnosis until death. Time to death by groups was compared using unweighted Kaplan-Meier 
curves and univariable and multivariable Cox regression analysis with baseline fixed covariates. The 
effect of treatment was shown by means of unadjusted and adjusted hazard ratio (HR) with 95%CI. 
Two key confounders were identified as carina involvement and extensive involvement, as the most 
likely causes of treatment group assignment and outcome risk.  In order to test the hypothesis that 
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the difference between treatment groups might vary according to mutational status, severity of 
CAO and unfavorable location of the stenosis, we formally included an interaction term in the Cox 
regression model. Results were then showed after categorizing the population in two strata using 
alternatively categorical separation for dichotomous variables (KRAS mutational status and left 
bronchus involvement) and the overall median value for continuous variables (percentage of lumen 
occlusion). Overall survival gain has been assessed according to the abovementioned stratification 
through ANOVA. The impact of the two different treatments on pre-specified secondary outcomes 
was carried out through Fisher’s exact test. Subgroup analysis according to interventional treatment 
procedure (debulking alone, stenting alone and both procedures) was also performed through 
Fisher’s exact test. A two-sided test of less than 0.05 was considered statistically significant.  
Statistical analyses were performed using SPSS version 25.0 (IBM Corp.New York, NY, USA) and 
Graphpad prism version 8.0 (Graphpad Software, Inc. La Jolla, Ca, USA) unless otherwise indicated. 
 
 
Results 
Population 
A total amount of 7243 patients diagnosed with NSCLC were referred to center A and B over the 
considered period. Out of them, 730 (10%) presented CAO > 50% at the CT scan at the time of 
diagnosis. Among the 188 eligible subjects, 100 patients with CAO and stage IIIB NSCLC were 
included in the study. Their median follow-up from diagnosis was 21 (IQR=9-36) months. Study flow-
chart is shown in Figure 1.  
Demographics, type and site of malignancies, degree of CAO, mutational state of cancer and 
oncological therapies are presented in Table 1. Forty patients who underwent cancer therapy alone, 
represented the ST group, whereas 60 patients of the IT group underwent endoscopic treatment 
plus standard chemotherapy/radiotherapy. The two groups did not show differences in terms of 
demographic characteristics, degree of stenosis, histology, mutational status of cancer and modality 
of standard treatment (Table 1). Patients in IT group showed an higher prevalence of extensive 
stenosis (25% VS 5%, p=0.01) and carina involvement (25% VS 5%, p=0.01) as compared to ST.  
Overall, 90 patients received sequential chemo-radiotherapy with no difference between groups 
(p=0.5). Groups did not differ in the type of chemotherapy received (Table S1, supplementary 
materials). Types of recanalization techniques and complications related to endoscopic intervention 
as reported in the IT group are shown in Table 2.  
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Outcomes 
Unadjusted Kaplan-Meier estimates showed the beneficial effect of IT compared to ST on 1-year 
survival (HR=2.1 95%CI[1.1-4.8], p=0.003) (Figure 2, panel A). After controlling for the key identified 
confounders of carina and extensive involvement results were almost superimposable confirming 
the treatment difference observed in the unadjusted analysis (Table 3). Moreover, the stratified 
analyses showed that this difference varied by the degree of occlusion, the lack of main bronchus 
involvement, and the KRAS molecular status (Table 3) even after adjusting for the usual set of 
confounders. Kaplan-Meier curves also showed a significant survival benefit at 1-year for the 
abovementioned patients’ strata when receiving IT as compared with ST (Figure A, panel B-D). 
Overall survival was longer in IT group although not statistically significant (23.7 months VS 19.2 
months, p=0.2). IT group showed a significantly higher survival gain over ST when patients had KRAS 
mutation (7.6 months VS 0.8 months, <0.0001), a lumen occlusion > 65% (6.6 months VS 2.9 months, 
<0.001), and no involvement of left bronchus (7 months VS 2.3 months, <0.0001) (Figure 3).  
Finally, IT showed a statistically significant favorable difference in terms of overall new 
hospitalizations (p=0.03), symptom-free interval (p=0.02), and onset of atelectasis (p=0.01), but not 
for occurrence of infections or hemorrhage (p=0.7 and p=0.8 respectively), onset of respiratory 
failure (p=0.1),  use of palliative care (p=0.9) (Table 4). Subgroups analysis within interventional 
procedures showed that debulking alone was significantly associated with higher incidence of 
respiratory failure and re-hospitalization as compared to stenting alone or both the procedures 
(p=0.002 an p=0.001, Table 3, supplementary materials). 
 
Discussion 
This study shows that the integration of interventional bronchoscopy (used outside palliation) with 
chemotherapy/radiotherapy in the management of IIIB NSCLC with CAO has a significant impact on 
the patient's prognosis. Moreover, the greater gain in life expectancy would be closely related to 
cancer’s anatomical (airway occlusion> 65%, no left mainstem occlusion), and molecular (KRAS-
mutant NSCLC) features.  
The prognosis of stage IIIB lung cancer is poor, and local control as well as systemic treatment are 
essential. The standard of care in unresectable stage III disease is a combination of platinum-based 
chemotherapy with radiation therapy (1). In recent years, the introduction of target therapy and 
immune-checkpoint inhibitors opened up new perspectives of treatment. In particular, the synergic 
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effect between immune therapy and radiotherapy has been recently proved, thus this combination 
has become a new standard in stage III patients (2,3,12).  
A proportion of IIIB NSCLC has a central airway occlusion that can occur at onset or during the course 
of the disease (4-5). In these patients, loco-regional progression of the disease can be one of the 
main causes of cancer-related death. Therefore, timing and technique of local disease control could 
have a significant impact on survival. Interventional bronchoscopy allows for rapid recanalization of 
airway obstruction, and it can be useful in locoregional control, by integrating with chemo-radiant 
treatment in patients with locally advanced NSCLC (10). Some studies show that the technical 
success rate of this treatment, defined as restoration of airway patency of at least 50% of the original 
airway diameter, approximates 90% in experienced centers (9, 13-14).  
Although the role of interventional bronchoscopy in the palliation of symptoms is well recognized, 
no data are currently available on the prognostic impact when using this technique in association 
with chemo/radiotherapy in stage IIIB NSCLC. Retrospectively, we were able to show a clear 1-year 
survival advantage when local interventional bronchoscopy is combined with medical therapies in 
patients with CAO.  
Although this result appears relevant, some considerations must be taken regarding the timing of 
intervention, the real impact of the technique on life expectancy, and the influence of cancer’s 
molecular features. 
First, the threshold of airway narrowing requiring interventional bronchoscopy is not standardized. 
Being considered palliative, endoscopic intervention is often performed when symptoms are 
present, and the degree of obstruction is very severe (10). Dyspnea in patients with CAO is not 
related to the alteration of gas exchange, but to the increased work of breathing required to 
maintain a normal flow of air delivered to and from the lung. Therefore, at least theoretically, 
pressure drop (ΔP) over the stenosis is the main parameter that can be considered as a cause of 
increased work of breathing and appearances of symptoms. In a computational fluid dynamics (CFD) 
study, flow patterns and ΔP over different degrees of tracheal stenosis artificially inserted into a 
three-dimensional upper airway model were assessed. ΔP over the stenosis was seen to increase 
dramatically only if >70% of tracheal lumen was occluded (15). Thus, bronchoscopy treatment in 
NSCLC is often proposed when the narrowing of the airways is extreme, and the risks of the 
intervention can be relevant. In our cohort, we therefore excluded patients with severe stenosis 
(>80%) and patients who required emergency intervention due to respiratory distress. 
Notwithstanding, present data suggest that interventional bronchoscopy over standard treatment, 
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may have a potential impact on outcome when proposed early in the management of stage IIIB 
NSCLC with CAO.  
Second, we should consider which is the real advantage in survival following interventional 
bronchoscopy in stage IIIB NSCLC. Previous studies have analyzed the outcome of NSCLC patients 
undergoing interventional bronchoscopy in a heterogeneous population, mixing up locally advanced 
NSCLC and stage IV, without a reliable control group, providing inconclusive results (16-24). Some 
data suggest that there is no difference in survival between patients free from CAO receiving 
chemotherapy, compared to those symptomatics who underwent successful interventional 
bronchoscopy followed by adjuvant chemotherapy (16). In our study, the different approach to 
endoscopic treatment of CAO (stenosis > 50%) allowed the enrollment of a reliable control group. 
In addition, only stage IIIB patients were considered for the study main purpose. It may be argued 
that non-surgically appropriate stage IIIA patients could benefit from interventional treatment. 
However, we decided to include only stage IIIB in the study in order to obtain a more reliable survival 
gain on the analysis performed. Indeed, 1-year survival significantly improved in the IT group 
compared to ST, however, if we consider the gain in life expectancy, a substantial survival effect was 
found in specific subsets of patients. Obstruction > 65% of the airway lumen, and no left mainstem 
occlusion were two anatomical features associated with a significant gain in survival. While it may 
be intuitive that resolving airway obstruction > 65% can result in a survival advantage, the 
explanation regarding the involvement of the left mainstem on the prognosis is less self-evident. 
Several studies have evaluated the technical success rate of therapeutic bronchoscopy in CAO, 
raising up the issue of patient selection (9,25). In the multi-institutional ACCP Quality Improvement 
Registry Evaluation, and Education (AQuIRE) registry, left mainstem obstruction was an unfavorable 
factor for the technical success of interventional bronchoscopy (9). Therefore, this result in our 
study could be explained by the greater technical difficulty in performing rigid bronchoscopy in cases 
of CAO with distal involvement of the left main bronchus.  
Third, molecular cancer features also had the greatest impact on gain in life expectancy. In our 
cohort, patients with KRAS-mutant NSCLC had 7.6 months gain in life expectancy in IT patients 
compared to ST. Although there is no a valid cut-off to define the survival gain as clinically relevant, 
some studies indicate a threshold greater than 4-5 months to consider a solid therapeutic progress 
(26-28). Moreover, considering that unresectable stage IIIB NSCLC is an aggressive disease with poor 
outcome, the gain in life expectancy found in the IT group is an impressive result. KRAS mutations 
are found in approximately 20-25% of lung adenocarcinomas in Western countries and in 10-15% 
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of cases in Asia (29-31). The mutation occurs mainly at codon 12 (>80%) and 13, causing a 
constitutive activation of the RAS oncoprotein and its intracellular pathways, resulting in 
uncontrolled cell proliferation and abnormal cell survival (32). Considering that KRAS-mutant lung 
cancer has been generally associated with lower survival and lower sensitivity to chemotherapy or 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, it is reasonable to assume that 
in this subset of patients standard chemotherapy/radiotherapy is unable to achieve the local control 
of occlusive disease. 
Although present findings are intriguing, we cannot draw a definitive conclusion due to several 
limitations of the study. This is mainly because of the retrospective design and the limited sample 
size, whose calculation might have been biased. Last, patients have been treated in centers with 
high expertise in interventional pulmonology, therefore the validity of data cannot be extrapolated 
for all. Notwithstanding, results are promising and suggest that, interventional bronchoscopy should 
be considered early as an integral part of management of patients with NSCLC stage IIIB and CAO. 
 
Conclusions 
In patients with NSCLC stage IIIB and associated CAO, interventional bronchoscopy does not target 
only a palliative purpose but might impact survival. Genetic and anatomic phenotyping might allow 
identifying those patients who are more likely to gain in life expectancy from endoscopic 
intervention. Further prospective investigations in larger cohorts is warranted to confirm results.  
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Figure legends 
Fig. 1. Flow chart for patients in this study. 
 
Fig. 2. Kaplan-Mayer curves showing impact of integrated treatment compared to standard therapy 
on 1-year survival for the overall population (panel A), for patients presenting K-RAS mutation (panel 
B), for patients with lumen occlusion > 65% (panel C) and for patients with lack of left bronchus 
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involvement (panel D).   
 
Fig. 3. Comparison of survival gain of integrated treatment over standard therapy for patients 
presenting K-RAS mutation (left side), for patients with lumen occlusion > 65% (central part) and for 
patients with lack of left bronchus involvement (right side).   
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Abstract 
Objectives 
Despite new therapeutic perspectives, the presence of central airways occlusion (CAO) in patients 
with locally advanced non-small cell lung cancer (NSCLC) is associated with poor survival. There is 
no clear evidence on the clinical impact of interventional bronchoscopy as a part of an integrated 
treatment to cure these patients.  
Materials and methods 
This retrospective cohort study was conducted in two teaching hospitals over a 10 years period 
(January 2010-January 2020) comparing patients with NSCLC at stage IIIB and CAO at disease onset 
treated with chemotherapy/radiotherapy (standard therapy-ST) with those receiving interventional 
bronchoscopy plus ST (integrated treatment-IT). Primary outcome was 1-year survival. The onset of 
respiratory events, symptoms-free interval, hospitalization, need for palliation, and overall mortality 
served as secondary outcomes.  
Results 
A total of 100 patients were included, 60 in the IT and 40 in the ST group. Unadjusted Kaplan-Meier 
estimates showed greater effect of IT compared to ST on 1-year survival (HR=2.1 95%CI[1.1-4.8], 
p=0.003). IT showed a significantly higher survival gain over ST in those patients showing KRAS 
mutation (7.6 VS 0.8 months,<0.0001), a lumen occlusion >65% (6.6 VS 2.9 months,<0.001), and 
lacking the involvement of left bronchus (7 VS 2.3 months,<0.0001). Compared to ST, IT also showed 
a favorable difference in terms of new hospitalizations (p=0.03), symptom-free interval (p=0.02), 
and onset of atelectasis (p=0.01). 
Conclusions 
In patients with NSCLC stage IIIB and CAO, additional interventional bronchoscopy might impact on 
1-year survival. Genetic and anatomic phenotyping might allow identifying those patients who may 
gain life expectancy from the endoscopic intervention. 
 
 
Key words: Non-small cell lung cancer, central airway obstruction, therapeutic bronchoscopy, 
mechanical debulking, airway stent, KRAS-mutant tumors. 
Abbreviations: CAO = central airway obstruction, CT = chemotherapy, RT = radiation therapy, ST = 
standard therapy, IT integrated treatment, NSCLC = Non-Small Cell Lung Cancer, IQR = interquartile 
ranges; EGFR = epidermal growth factor receptor; BRAF = v-raf murine sarcoma viral oncogene 
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homolog B1; KRAS = Kirsten rat sarcoma; ALK = Anaplastic lymphoma kinase; PDL1 = programmed 
death-ligand 1; CHT = chemotherapy; RT = radiotherapy; TKI = tyrosine kinase inhibitor. 
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Introduction 
Stage III locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous condition affecting 
about one-third of the overall patients (1). Usually, therapeutic approach consists of a combination 
of local therapy (radiotherapy) with systemic platinum-based doublet chemotherapy. However, the 
prognosis remains poor, with only a limited improvement in survival achieved over the past 10 
years. Recently, it has been shown that durvalumab significantly prolonged progression-free and 
overall survival, as compared with placebo, among patients with unresectable stage III NSCLC after 
concurrent chemoradiotherapy (2-3). Despite this new therapeutic perspective, a group of patients 
with locally advanced NSCLC already presents at diagnosis with an occlusion of the central airways 
which can result in worse life expectancy.  
Malignant central airway obstruction (CAO) is defined as any malignant disease process that causes 
significant alteration of patency of the trachea, main bronchi, or bronchus intermedius (4). It is 
estimated that 20-30% of patients with lung cancer will develop CAO with the associated 
complications (dyspnoea, atelectasis, post-obstructive pneumonia), and 40% of tumor-related 
mortality can be attributed to locoregional progression of lung cancer (5). Furthermore, some 
studies show that in advanced lung cancer, CAO is associated with poor survival when adjusted for 
age, gender and stage of cancer (6). In particular, in unresectable NSCLC stage IIIB with CAO, 
locoregional control of neoplastic disease could have a significant impact on survival.  
Short-course of palliative radiotherapy may achieve significant control of airway stenosis in 23-54% 
of patients within 24 days (7-8). Interventional bronchoscopy (mechanical debulking and thermal 
techniques or implementation with tracheal/bronchial prostheses) allows for immediate relieving 
of airway occlusion in 93% of cases, leading to a significant improvement in symptoms and quality 
of life in almost 50% of patients, although some anatomical features (i.e. left bronchus involvement) 
alongside specific mutational status may worsen outcomes. (9).  
To date, there is currently no reliable evidence regarding the impact of interventional bronchoscopy 
on survival in locally advanced NSCLC (10). The main purpose of this study is therefore to evaluate 
the clinical impact of interventional bronchoscopy plus chemotherapy/radiotherapy (integrated 
treatment) compared with chemotherapy/radiotherapy alone (standard therapy) in the 
management of patients with stage IIIB NSCLC with CAO. 
 
Materials and methods 
Design 
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EVERMORE is a retrospective, multicenter observational cohort study carried out in two units of 
Emilia Romagna region (Italy): Diagnostic and Interventional Bronchoscopy Unit of the University 
Hospital of Modena, and Thoracic Endoscopy Unit of the Santa Maria Nuova Hospital of Reggio 
Emilia. The two units have different protocols routinely applied to treat CAO in locally advanced 
NSCLC. In center A endoscopic treatment is performed early when stenosis exceeds 50%, even in 
the absence of respiratory symptoms, while in center B the other endoscopic treatment is 
performed only in CAO with associated respiratory symptoms. In center A patients underwent stent 
positioning in case of mixed (intrinsic/extrinsic) CAO and if after debulking procedure a significant 
(>50%) stenosis persists. All interventional procedures have been performed in the operating room 
with a Dumon rigid bronchoscope (Efer Medical, La Ciotat, Cedex, France) under general anesthesia. 
Neodymium-doped yttrium aluminium garnet (Nd-YAG) laser photoresection (KLS Martin, Diode-
pumped Nd: YAG laser Limax ®, Germany) was performed at 15-30 watts and pulse duration of 0.5-
1.0s. In cases with extrinsic compression from malignant occlusion, or whenever indicated, a silicone 
stent (NOVATECH Doumon stents, Boston Medical Products, Inc., Westborough, MA, USA) was 
placed. 
All patients had undergone flexible bronchoscopy whose reports were considered, alongside CT 
scan images, in order to estimate the extension of CAO. Malignant CAO was defined as a luminal 
occlusion of > 50% in the trachea, mainstem bronchi and/or bronchus intermedius, consistent with 
previous studies (9). Clinical staging was based on the 8th lung cancer TNM classification (11). 
This study was approved by Local Ethics Committee (Prot. AOU 0013040/19 and 
276/2019/OSS/AOUMO) and registered on clinicaltrial.gov (trial registration number: 
NCT03903315).  
 
Population and measures 
From January 2010 to January 2020 we collected clinical, endoscopic and radiological data of NSCLC 
patients with CAO admitted in the two units. Inclusion criteria were as follows: age >18 years, 
candidates for anticancer treatment with cytologic and/or histologic diagnosis of NSCLC stage IIIB 
and CAO at onset of disease, performance status < 2, CAO in between 50% and 80%. Patients were 
excluded if aged > 80, and/or with end-stage chronic obstructive pulmonary disease, interstitial lung 
disease, life-threatening stenosis requiring urgent endoscopy. 
Chart review, health record, medical record, archival data analysis was performed at each center. 
The following data have been collected in an electronic database: demographic data, Charlson Index 
Formatted: Font: 12 pt, Not Highlight
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for comorbidity assessment, histopathology, genetic analysis of the tumor (EGFR and KRAS 
mutations, ALK translocations), PD-L1 expression, localization of CAO, degree of airway obstruction, 
the type of anticancer treatment (chemotherapy, radiotherapy, tyrosine kinase inhibitors, 
immunotherapy), type of endoscopic treatment (stent, laser and mechanical debulking), 
complications of endoscopic treatment, onset of respiratory events (atelectasis, infections, 
respiratory failure, hemorrhage), 1-year and overall survival, hospitalization rate, need for palliative 
care, symptoms-free interval. Patients included were divided into two groups: 1) integrated 
treatment-IT (patients undergoing endoscopic treatment plus chemotherapy/radiotherapy); 2) 
standard treatment-ST (chemotherapy/radiotherapy alone). 
 
Outcomes 
The primary purpose was to evaluate the impact on 12-month survival in patients with stage IIIB 
NSCLC with CAO in the two groups.  
The secondary aim was similarly to compare the onset of respiratory events, hospitalization, need 
for palliative care, symptoms-free interval and overall survival (see in the previous paragraph). 
 
Statistical Analysis 
Sample size calculation was performed assuming an estimated 1-year mortality rate of 45% for IIIB 
NSCLC patients receiving ST with an estimated reduction by 40% in those receiving IT (data derived 
from an exploration analysis in 15 patients). Assuming α= 0.05, power 80% and an enrollment ratio 
of 1:1.5 (according to the overall number of patients referred at each center), a sample size of 100 
patients was calculated to perform analysis on the primary outcome.  
Baseline characteristics of the participants treated with IT and ST were compared. Continuous 
variables were expressed as median and interquartile ranges (IQR) and compared by Kruskal Wallis 
test. Categorical variables were expressed as numbers and percentages (%) and compared by χ2 test 
or Fisher’s exact test across the integrated and the standard treatment groups.  
The 1-year survival analysis was performed with participants’ follow-up accrued from the date of 
diagnosis until death. Time to death by groups was compared using unweighted Kaplan-Meier 
curves and univariable and multivariable Cox regression analysis with baseline fixed covariates. The 
effect of treatment was shown by means of unadjusted and adjusted hazard ratio (HR) with 95%CI. 
Two key confounders were identified as carina involvement and extensive involvement, as the most 
likely causes of treatment group assignment and outcome risk.  In order to test the hypothesis that 
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the difference between treatment groups might vary according to mutational status, severity of 
CAO and unfavorable location of the stenosis, we formally included an interaction term in the Cox 
regression model. Results were then showed after categorizing the population in two strata using 
alternatively categorical separation for dichotomous variables (KRAS mutational status and left 
bronchus involvement) and the overall median value for continuous variables (percentage of lumen 
occlusion). Overall survival gain has been assessed according to the abovementioned stratification 
through ANOVA. The impact of the two different treatments on pre-specified secondary outcomes 
was carried out through Fisher’s exact test. Subgroup analysis according to interventional treatment 
procedure (debulking alone, stenting alone and both procedures) was also performed through 
Fisher’s exact test. A two-sided test of less than 0.05 was considered statistically significant.  
Statistical analyses were performed using SPSS version 25.0 (IBM Corp.New York, NY, USA) and 
Graphpad prism version 8.0 (Graphpad Software, Inc. La Jolla, Ca, USA) unless otherwise indicated. 
 
 
Results 
Population 
A total amount of 7243 patients diagnosed with NSCLC were referred to center A and B over the 
considered period. Out of them, 730 (10%) presented CAO > 50% at the CT scan at the time of 
diagnosis. Among the 188 eligible subjects, 100 patients with CAO and stage IIIB NSCLC were 
included in the study. Their median follow-up from diagnosis was 21 (IQR=9-36) months. Study flow-
chart is shown in Figure 1.  
Demographics, type and site of malignancies, degree of CAO, mutational state of cancer and 
oncological therapies are presented in Table 1. Forty patients who underwent cancer therapy alone, 
represented the ST group, whereas 60 patients of the IT group underwent endoscopic treatment 
plus standard chemotherapy/radiotherapy. The two groups did not show differences in terms of 
demographic characteristics, degree of stenosis, histology, mutational status of cancer and modality 
of standard treatment (Table 1). Patients in IT group showed an higher prevalence of extensive 
stenosis (25% VS 5%, p=0.01) and carina involvement (25% VS 5%, p=0.01) as compared to ST.  
Overall, 90 patients received sequential chemo-radiotherapy with no difference between groups 
(p=0.5). Groups did not differ in the type of chemotherapy received (Table S1, supplementary 
materials). Types of recanalization techniques and complications related to endoscopic intervention 
as reported in the IT group are shown in Table 2.  
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Outcomes 
Unadjusted Kaplan-Meier estimates showed the beneficial effect of IT compared to ST on 1-year 
survival (HR=2.1 95%CI[1.1-4.8], p=0.003) (Figure 2, panel A). After controlling for the key identified 
confounders of carina and extensive involvement results were almost superimposable confirming 
the treatment difference observed in the unadjusted analysis (Table 3). Moreover, the stratified 
analyses showed that this difference varied by the degree of occlusion, the lack of main bronchus 
involvement, and the KRAS molecular status (Table 3) even after adjusting for the usual set of 
confounders. Kaplan-Meier curves also showed a significant survival benefit at 1-year for the 
abovementioned patients’ strata when receiving IT as compared with ST (Figure A, panel B-D). 
Overall survival was longer in IT group although not statistically significant (23.7 months VS 19.2 
months, p=0.2). IT group showed a significantly higher survival gain over ST when patients had KRAS 
mutation (7.6 months VS 0.8 months, <0.0001), a lumen occlusion > 65% (6.6 months VS 2.9 months, 
<0.001), and no involvement of left bronchus (7 months VS 2.3 months, <0.0001) (Figure 3).  
Finally, IT showed a statistically significant favorable difference in terms of overall new 
hospitalizations (p=0.03), symptom-free interval (p=0.02), and onset of atelectasis (p=0.01), but not 
for occurrence of infections or hemorrhage (p=0.7 and p=0.8 respectively), onset of respiratory 
failure (p=0.1),  use of palliative care (p=0.9) (Table 4). Subgroups analysis within interventional 
procedures showed that debulking alone was significantly associated with higher incidence of 
respiratory failure and re-hospitalization as compared to stenting alone andor both the procedures 
(p=0.002 an p=0.001, Table 3, supplementary materials). 
 
Discussion 
This study shows that the integration of interventional bronchoscopy (used outside palliation) with 
chemotherapy/radiotherapy in the management of IIIB NSCLC with CAO has a significant impact on 
the patient's prognosis. Moreover, the greater gain in life expectancy would be closely related to 
cancer’s anatomical (airway occlusion> 65%, no left mainstem occlusion), and molecular (KRAS-
mutant NSCLC) features.  
The prognosis of stage IIIB lung cancer is poor, and local control as well as systemic treatment are 
essential. The standard of care in unresectable stage III disease is a combination of platinum-based 
chemotherapy with radiation therapy (1). In recent years, the introduction of target therapy and 
immune-checkpoint inhibitors opened up new perspectives of treatment. In particular, the synergic 
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effect between immune therapy and radiotherapy has been recently proved, thus this combination 
has become a new standard in stage III patients (2,3,12).  
A proportion of IIIB NSCLC has a central airway occlusion that can occur at onset or during the course 
of the disease (4-5). In these patients, loco-regional progression of the disease can be one of the 
main causes of cancer-related death. Therefore, timing and technique of local disease control could 
have a significant impact on survival. Interventional bronchoscopy allows for rapid recanalization of 
airway obstruction, and it can be useful in locoregional control, by integrating with chemo-radiant 
treatment in patients with locally advanced NSCLC (10). Some studies show that the technical 
success rate of this treatment, defined as restoration of airway patency of at least 50% of the original 
airway diameter, approximates 90% in experienced centers (9, 13-14).  
Although the role of interventional bronchoscopy in the palliation of symptoms is well recognized, 
no data are currently available on the prognostic impact when using this technique in association 
with chemo/radiotherapy in stage IIIB NSCLC. Retrospectively, we were able to show a clear 1-year 
survival advantage when local interventional bronchoscopy is combined with medical therapies in 
patients with CAO.  
Although this result appears relevant, some considerations must be taken regarding the timing of 
intervention, the real impact of the technique on life expectancy, and the influence of cancer’s 
molecular features. 
First, the threshold of airway narrowing requiring interventional bronchoscopy is not standardized. 
Being considered palliative, endoscopic intervention is often performed when symptoms are 
present, and the degree of obstruction is very severe (10). Dyspnea in patients with CAO is not 
related to the alteration of gas exchange, but to the increased work of breathing required to 
maintain a normal flow of air delivered to and from the lung. Therefore, at least theoretically, 
pressure drop (ΔP) over the stenosis is the main parameter that can be considered as a cause of 
increased work of breathing and appearances of symptoms. In a computational fluid dynamics (CFD) 
study, flow patterns and ΔP over different degrees of tracheal stenosis artificially inserted into a 
three-dimensional upper airway model were assessed. ΔP over the stenosis was seen to increase 
dramatically only if >70% of tracheal lumen was occluded (15). Thus, bronchoscopy treatment in 
NSCLC is often proposed when the narrowing of the airways is extreme, and the risks of the 
intervention can be relevant. In our cohort, we therefore excluded patients with severe stenosis 
(>80%) and patients who required emergency intervention due to respiratory distress. 
Notwithstanding, present data suggest that interventional bronchoscopy over standard treatment, 
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may have a potential impact on outcome when proposed early in the management of stage IIIB 
NSCLC with CAO.  
Second, we should consider which is the real advantage in survival following interventional 
bronchoscopy in stage IIIB NSCLC. Previous studies have analyzed the outcome of NSCLC patients 
undergoing interventional bronchoscopy in aan heterogeneous populations, mixing up locally 
advanced NSCLC and stage IV, without a reliable control group, providing inconclusive results (16-
24). Some data suggest that there is no difference in survival between patients free from CAO 
receiving chemotherapy, compared to those symptomatics who underwent successful 
interventional bronchoscopy followed by adjuvant chemotherapy (16). In our study, the different 
approach to endoscopic treatment of CAO (stenosis > 50%) allowed the enrollment of a reliable 
control group. In addition, only stage IIIB patients were considered for the study main purpose. It 
may be argued that non-surgically appropriate stage IIIA patients could benefit from interventional 
treatment. However, we decided to include only stage IIIB in the study in order to obtain a more 
reliable analysis on survival gain on the analysis performed. Indeed, 1-year survival significantly 
improved in the IT group compared to ST, however, if we consider the gain in life expectancy, a 
substantial survival effect was found in specific subsets of patients. Obstruction > 65% of the airway 
lumen, and no left mainstem occlusion were two anatomical features associated with a significant 
gain in survival. While it may be intuitive that resolving airway obstruction > 65% can result in a 
survival advantage, the explanation regarding the involvement of the left mainstem on the 
prognosis is less self-evident. Several studies have evaluated the technical success rate of 
therapeutic bronchoscopy in CAO, raising up the issue of patient selection (9,25). In the multi-
institutional ACCP Quality Improvement Registry Evaluation, and Education (AQuIRE) registry, left 
mainstem obstruction was an unfavorable factor for the technical success of interventional 
bronchoscopy (9). Therefore, this result in our study could be explained by the greater technical 
difficulty in performing rigid bronchoscopy in cases of CAO with distal involvement of the left main 
bronchus.  
Third, molecular cancer features also had the greatest impact on gain in life expectancy. In our 
cohort, patients with KRAS-mutant NSCLC had 7.6 months gain in life expectancy in IT patients 
compared to ST. Although there is no a valid cut-off to define the survival gain as clinically relevant, 
some studies indicate a threshold greater than 4-5 months to consider a solid therapeutic progress 
(26-28). Moreover, considering that unresectable stage IIIB NSCLC is an aggressive disease with poor 
outcome, the gain in life expectancy found in the IT group is an impressive result. KRAS mutations 
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are found in approximately 20-25% of lung adenocarcinomas in Western countries and in 10-15% 
of cases in Asia (29-31). The mutation occurs mainly at codon 12 (>80%) and 13, causing a 
constitutive activation of the RAS oncoprotein and its intracellular pathways, resulting in 
uncontrolled cell proliferation and abnormal cell survival (32). Considering that KRAS-mutant lung 
cancer has been generally associated with lower survival and lower sensitivity to chemotherapy or 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, it is reasonable to assume that 
in this subset of patients standard chemotherapy/radiotherapy is unable to achieve the local control 
of occlusive disease. 
Although present findings are intriguing, we cannot draw a definitive conclusion due to several 
limitations of the study. This is mainly because of the retrospective design and the limited sample 
size, whose calculation might have been biased. Last, patients have been treated in centers with 
high expertise in interventional pulmonology, therefore the validity of data cannot be extrapolated 
for all. Notwithstanding, results are promising and suggest that, interventional bronchoscopy should 
be considered early as an integral part of management of patients with NSCLC stage IIIB and CAO. 
 
Conclusions 
In patients with NSCLC stage IIIB and associated CAO, interventional bronchoscopy does not target 
only a palliative purpose but might impact survival. Genetic and anatomic phenotyping might allow 
identifying those patients who are more likely to gain in life expectancy from endoscopic 
intervention. Further prospective investigations in larger cohorts is warranted to confirm results.  
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Figure legends 
Fig. 1. Flow chart for patients in this study. 
 
Fig. 2. Kaplan-Mayer curves showing impact of integrated treatment compared to standard therapy 
on 1-year survival for the overall population (panel A), for patients presenting K-RAS mutation (panel 
B), for patients with lumen occlusion > 65% (panel C) and for patients with lack of left bronchus 
 18 
involvement (panel D).   
 
Fig. 3. Comparison of survival gain of integrated treatment over standard therapy for patients 
presenting K-RAS mutation (left side), for patients with lumen occlusion > 65% (central part) and for 
patients with lack of left bronchus involvement (right side).   
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Table 1 
 Variable 
 
Cohort 
p value 
Total  
n=100 
Integrated 
treatm
ent n= 60  
 
Standard 
care n=40 
Age, score (IQ
R) 
74 (68-79.3) 
73.3 (66.3-78.4) 
76 (71-80.5) 
 n.s (0.2) 
M
ale, n (%
) 
68 (68) 
37 (62) 
31 (78) 
 n.s. (0.1) 
Charlson index, score (IQ
R) 
5 (5-7) 
5 (5-7) 
5 (5-6) 
n.s. (0.4) 
Stenosis location 
 
 
 
 
Trachea, n (%
) 
21 (21) 
16 (27) 
5 (13) 
 n.s (0.1) 
M
ain right bronchus, n (%
) 
60 (60) 
35 (58) 
25 (63) 
n.s. (0.8) 
M
ain left bronchus, n (%
) 
47 (47) 
29 (48) 
18 (45) 
n.s. (0.8) 
Carina, n (%
) 
17 (17) 
15 (25) 
2 (5) 
0.01 
Extensive involvem
ent 
17 (17) 
15 (25) 
2 (5) 
0.01 
O
bstruction, %
 (IQ
R) 
65 (60-75) 
70 (65-75) 
65 (65-75) 
n.s. (0.29) 
Histotype 
 
 
 
 
Adenocarcinom
a, n (%
) 
28 (28) 
13 (22) 
15 (38) 
n.s. (0.1) 
Squam
ocellular carcinom
a, n (%
) 
57 (57) 
31 (53) 
26 (65) 
n.s. (0.2) 
O
thers *, n (%
) 
15 (15) 
11 (18) 
4 (10) 
n.s. (0.4) 
M
utational status 
 
 
 
 
EGFR, n (%
) 
12 (12) 
9 (15) 
3 (8) 
n.s. (0.4) 
KRAS, n (%
) 
21 (21) 
12 (20) 
9 (23) 
n.s. (0.8) 
BRAF, n (%
) 
0 (0) 
0 (0) 
0 (0) 
n.s. (0.9) 
ALK, n (%
) 
2 (2) 
0 (0) 
2 (5) 
n.s. (0.2) 
PDL1***, n (%
) 
14 (14) 
9 (15) 
5 (13) 
n.s. (0.8) 
Treatm
ent 
 
 
 
 
Traditional CHT/RT, n (%
) 
90 (90) 
55 (92) 
35 (87.5) 
n.s. (0.5) 
TKI, n (%
) 
12 (12) 
9 (15) 
3 (8) 
n.s. (0.4) 
Im
m
unotherapy, n (%
) 
17 (17) 
11 (18) 
6 (15) 
n.s. (0.8) 
Table
  Dem
ographic and clinical characteristics of the general population and on the basis of treatm
ent. The data are presented as a num
erical and 
percentage value for dichotom
ic variables and as m
edian and interquartile ranges for continuous variables. The statistical significance w
as set for 
p<0.05.* O
thers includes N
O
S (n=10) and large cells carcinom
a (n=5) ** * PDL-1 is referred to patients w
ith a PDL-1 expression above 50%
.  PDL-1 
feature is referred to patients w
ith a PDL-1 expression above 50%
. 
IQ
R = interquartile ranges; EGFR = epiderm
al grow
th factor receptor; BRAF = v-raf m
urine sarcom
a viral oncogene hom
olog B1; KRAS = Kirsten rat 
sarcom
a; ALK = Anaplastic lym
phom
a kinase; PDL1 = program
m
ed death-ligand 1; CHT = chem
otherapy; RT = radiotherapy; TKI = tyrosine kinase 
inhibitor. 
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Table 2 
 
 
Feature  
Stenting procedure, n (%) 54 (90) 
Type of stent  
Y, n (%) 24 (40) 
Single, n (%) 34 (60) 
Obstruction removal, n (%) 35 (58) 
Type of obstruction removal, n (%)  
Laser, n (%) 6 (17) 
Mechanical, n (%) 16 (46) 
Laser + mechanical, n (%) 13 (37) 
Complications at 1-year 10 (19) 
Post-obstructive pneumonia, n (%) 5 (9) 
Granulation, n (%) 8 (15) 
Dislocation, n (%) 8 (15) 
Removal, n (%) 9 (17) 
Occlusion, n (%) 6 (20) 
 
 
Technical endoscopic features and clinical events of patients that underwent integrated treatment. 
Data are presented as number and percentage. 
Six patients presented occlusion, further dislocation and subsequent removal of the stent; of them, 
5 patients presented post-obstructive pneumonia; two patient presented granulation and one of 
them underwent stent removal; two patients presented dislocation without occlusion and were 
further subjected to removal. 
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Table 3 
 
 Unadjusted and adjusted relative hazards of 12 months survival 
 Unadjusted HR 
(95%CI) 
p value Adjusted* HR 
(95%CI) 
p value 
 All cases 
Standard care 1  1  
Integrated care 2.1 (1.1-4.8) 0.003 1.9 (1-3.8) 0.02 
     
 Stratum % obstruction below 65 % 
Standard care 1  1  
Integrated care 1.5 (0.6-4) 0.3 1.4 (0.6-3.7) 0.4 
     
 Stratum % obstruction above 65 % 
Standard care 1  1  
Integrated care 4.1 (1.3-12.7) 0.01 3.7 (1.1-11.8) 0.01 
     
 Stratum mutational status KRAS+ 
Standard care 1  1  
Integrated care 8.3 (1.6-49) <0.001 5.5 (1.2-15) 0.02 
     
 Stratum mutational status KRAS- 
Standard care 1  1  
Integrated care 1.6 (0.67-4.1) 0.27 1.5 (0.6-4.5) 0.3 
     
 Stratum left bronchus involvement+ 
Standard care 1  1  
Integrated care 1.8 (0.65-5.2) 0.23 1.9 (0.7-6) 0.2 
     
 Stratum left bronchus involvement- 
Standard care 1  1  
Integrated care 3.2 (1.1-9.8) 0.03 3.4 (1.2-11.2) 0.02 
 
 
 
Hazard ratios from fitting a standard Cox regression model 
*Adjusted for carina and extensive involvement 
 
 
 
Table
Table 4 
  
O
utcom
e 
Cohort 
O
R 
p-value 
Total  
n=100 
Integrated treatm
ent 
n=60 
Standard care 
n=40 
 
Atelectasis, n (%
) 
28 (28) 
11 (18.3) 
17 (42.5) 
0.3 (0.12-0.76) 
0.01 
Rehospitalization, n (%
) 
34 (34) 
15 (25.9) 
26 (47.5) 
0.4 (0.17-0.9) 
0.03 
Infectious event, n (%
) 
28 (28) 
18 (30.5) 
10 (25) 
1.3 (0.5-3.4) 
n.s. (0.7) 
Haem
orrhagic event, n (%
) 
23 (23) 
13 (21.7) 
10 (25) 
0.8 (0.3-2.1) 
n.s. (0.8) 
Respiratory failure, n (%
) 
30 (29) 
14 (23.3) 
16 (40) 
0.46 (0.2-1.1) 
n.s (0.1) 
Palliative treatm
ents, n (%
) 
31 (31) 
16 (26.7) 
15 (37.5) 
1.1 (0.25-1.4) 
n.s. (0.9) 
Sym
ptom
s-free tim
e, m
onths (IQ
R) 
2.5 (1-5) 
4 (2-6) 
2 (1-4.5) 
0.4 (0.15-0.8) 
0.02 
  Clinical outcom
e for the general population and according to treatm
ent received. The data are presented as a num
bers and percentage value for 
dichotom
ic variables and as m
edian and interquartile ranges for continuous variables. The statistical significance w
as set for p<0.05. 
O
R = odds ratio; IQ
R = interquartile range 
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Table S1 
 Treatm
ent 
 
Cohort 
p value 
Total  
n=90 
Integrated 
treatm
ent n= 55  
 
Standard 
care n=35 
Pem
etrexed/carboplatin, n (%
) 
43 (48) 
26 (47) 
17 (49) 
n.s. (0.9) 
Pem
etrexed/cisplatin, n (%
) 
28 (31) 
18 (33) 
10 (29) 
n.s. (0.8) 
Gem
citabine/carboplatin, n (%
) 
12 (13) 
7 (13) 
5 (14) 
n.s. (0.9) 
Gem
citabine/cisplatin, n (%
) 
3 (3) 
2 (4) 
1 (3) 
n.s. (0.9) 
Placlitaxel/carboplatin, n (%
) 
4 (4) 
2 (4) 
2 (6) 
n.s. (0.6) 
  Dem
ographic and clinical characteristics of the general population and on the basis of treatm
ent. The data are presented as a num
erical and 
percentage value for dichotom
ic variables and as m
edian and interquartile ranges for continuous variables. The statistical significance w
as set for 
p<0.05. 
IQ
R = interquartile ranges; EGFR = epiderm
al grow
th factor receptor; BRAF = v-raf m
urine sarcom
a viral oncogene hom
olog B1; KRAS = Kirsten rat 
sarcom
a; ALK = Anaplastic lym
phom
a kinase; PDL1 = program
m
ed death-ligand 1; CHT = chem
otherapy; RT = radiotherapy; TKI = tyrosine kinase 
inhibitor. 
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Table 2 
 Sym
ptom
* 
 
Cohort 
p value 
Total  
n=100 
Integrated 
treatm
ent n= 60  
 
Standard 
care n=40 
Dyspnea, n (%
) 
25 (25) 
14 (23) 
11 (28) 
n.s. (0.6) 
Persistent cough, n (%
) 
 21 (21) 
12 (20) 
9 (23) 
n.s. (0.8) 
Hem
optysis, n (%
) 
10 (10) 
5 (8) 
5 (13) 
n.s. (0.5) 
W
heezing**, n (%
) 
7 (7) 
5 (8) 
2 (5) 
n.s. (0.5) 
N
o sym
ptom
s, n (%
) 
37 (38) 
24 (40) 
13 (33) 
n.s. (0.4) 
  Sym
ptom
s of the general population and on the basis of treatm
ent. The data are presented as a num
erical and percentage. The statistical 
significance w
as set for p<0.05. * “Sym
ptom
” is intended as the m
ain reported clinical m
anifestation. ** “W
heezing” is intended as any respiratory 
sounds suggestive for airw
ay lum
en narrow
ing.  
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Table 2 
 Variable 
 
Cohort 
p value 
Total  
n=60 
Debulking alone 
n= 6 
 
Stenting alone 
n=25 
Both procedures 
n=29 
Death at 12 m
onths, n (%
) 
13 (21.6) 
3 (50) 
5 (20) 
5 (17.2) 
n.s (0.2) 
Atelectasis, n (%
) 
11 (18.3) 
3 (50) 
4 (16) 
4 (13.8) 
n.s. (0.1) 
Rehospitalization, n (%
) 
15 (25.9) 
5 (83.3) 
6 (24) 
4 (13.8) 
0.002 
Infectious event, n (%
) 
18 (30.5) 
4 (66.7) 
6 (24) 
8 (27.6) 
n.s. (0.1) 
Hem
orrhagic event, n (%
) 
13 (21.7) 
2 (33.3) 
4 (16) 
7 (24.1) 
n.s. (0.6) 
Respiratory failure, n (%
) 
14 (23.3) 
5 (83.3) 
6 (24) 
3 (13.8) 
0.001 
Palliative treatm
ents, n (%
) 
16 (26.7) 
3 (50) 
5 (20) 
8 (27.6) 
n.s. (0.3) 
O
verall survival, m
onths (IQ
R) 
23.7 (8.7-40) 
18.5 (8.2-31.3) 
24.2 (10.2-37.4) 
25.2 (11.3-41) 
n.s. (0.47) 
Sym
ptom
s-free tim
e, m
onths (IQ
R) 
4 (2-6) 
2.5 (2-3.3) 
3.3 (2.4-5.3) 
4.7 (3.2-6) 
0.04 
  Clinical outcom
e for patients undergoing integrated treatm
ent and according to specific treatm
ent received. The data are presented as a num
bers 
and percentage value for dichotom
ic variables and as m
edian and interquartile ranges for continuous variables. The statistical significance w
as set 
for p<0.05. 
IQ
R = interquartile range 
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